Publications

BibTex format

@article{Lujan-Barroso:2020:10.1158/1055-9965.EPI-20-0184,
author = {Lujan-Barroso, L and Botteri, E and Caini, S and Ljungberg, B and Roswall, N and Tjønneland, A and Bueno-de-Mesquita, B and Gram, IT and Tumino, R and Kiemeney, LA and Liedberg, F and Stocks, T and Gunter, MJ and Murphy, N and Cervenka, I and Fournier, A and Kvaskoff, M and Häggström, C and Overvad, K and Lund, E and Waaseth, M and Fortner, RT and Kühn, T and Menéndez, V and Sánchez, M-J and Santiuste, C and Perez-Cornago, A and Zamora-Ros, R and Cross, AJ and Trichopoulou, A and Karakatsani, A and Peppa, E and Palli, D and Krogh, V and Sciannameo, V and Mattiello, A and Panico, S and van, Gils CH and Onland-Moret, NC and Barricarte, A and Amiano, P and Khaw, K-T and Boeing, H and Weiderpass, E and Duell, EJ},
doi = {10.1158/1055-9965.EPI-20-0184},
journal = {Cancer Epidemiology, Biomarkers and Prevention},
pages = {1654--1664},
title = {Menstrual factors, reproductive history, hormone use, and urothelial carcinoma risk: a prospective study in the EPIC cohort},
url = {http://dx.doi.org/10.1158/1055-9965.EPI-20-0184},
volume = {29},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Urothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk. METHODS: We used an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non-muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models. RESULTS: During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR≥5vs1 = 0.48; 0.25-0.90; Ptrend in parous women = 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR = 1.27; 1.03-1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non-muscle-invasive urothelial carcinoma risk was observed. CONCLUSIONS: Our results support that increasing the number of FTP may reduce urothelial carcinoma risk. IMPACT: More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.
AU  - Lujan-Barroso,L
AU  - Botteri,E
AU  - Caini,S
AU  - Ljungberg,B
AU  - Roswall,N
AU  - Tjønneland,A
AU  - Bueno-de-Mesquita,B
AU  - Gram,IT
AU  - Tumino,R
AU  - Kiemeney,LA
AU  - Liedberg,F
AU  - Stocks,T
AU  - Gunter,MJ
AU  - Murphy,N
AU  - Cervenka,I
AU  - Fournier,A
AU  - Kvaskoff,M
AU  - Häggström,C
AU  - Overvad,K
AU  - Lund,E
AU  - Waaseth,M
AU  - Fortner,RT
AU  - Kühn,T
AU  - Menéndez,V
AU  - Sánchez,M-J
AU  - Santiuste,C
AU  - Perez-Cornago,A
AU  - Zamora-Ros,R
AU  - Cross,AJ
AU  - Trichopoulou,A
AU  - Karakatsani,A
AU  - Peppa,E
AU  - Palli,D
AU  - Krogh,V
AU  - Sciannameo,V
AU  - Mattiello,A
AU  - Panico,S
AU  - van,Gils CH
AU  - Onland-Moret,NC
AU  - Barricarte,A
AU  - Amiano,P
AU  - Khaw,K-T
AU  - Boeing,H
AU  - Weiderpass,E
AU  - Duell,EJ
DO  - 10.1158/1055-9965.EPI-20-0184
EP  - 1664
PY  - 2020///
SN  - 1055-9965
SP  - 1654
TI  - Menstrual factors, reproductive history, hormone use, and urothelial carcinoma risk: a prospective study in the EPIC cohort
T2  - Cancer Epidemiology, Biomarkers and Prevention
UR  - http://dx.doi.org/10.1158/1055-9965.EPI-20-0184
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32467345
UR  - http://hdl.handle.net/10044/1/80585
VL  - 29
ER  -

Download

Professor Amanda Cross

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)